Retreatment of Patients With Metastatic Cutaneous Melanoma Who Relapse After Elective Checkpoint Inhibitor Discontinuation After a Complete Remission
The Oncologist · 2023
DOI: 10.1093/oncolo/oyad016 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Oncologist, 2023. Verfasst von Kaviyon Sadrolashrafi und 1 weiteren Autor:innen. Beteiligte Einrichtung: Kirk Kerkorian School of Medicine at UNLV, Las Vegas, NV, USA. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Checkpoint blockade has improved the response rate and survival in metastatic melanoma. Elective treatment discontinuation appears to be reasonable in most patients who have achieved a confirmed complete remission. It seems crucial to understand whether restarting immune checkpoint inhibitor therapy can induce additional responses or remissions in rare patients who relapse.
Methods
A retrospective analysis identified only 10 patients who relapsed after elective treatment discontinuation after a radiologically confirmed remission. These patients were retreated with single-agent PD-1 or combined CTLA-4 plus PD-1-directed monoclonal antibodies.
Results
We found an initial complete response rate of 20% (2 patients) following retreatment. With a median follow-up of 26 months, the addition of individualized salvage therapies converted an additional 4 patients to a 2nd remission. All 6 of these patients have again discontinued therapy. Three patients have died of metastatic melanoma, while another is receiving salvage therapy. Six of our 10 patients experienced grades 2-3 retreatment-related toxicity. There were no hospitalizations or fatalities.
Discussion
Retreatment of relapsing patients resulted in 20% complete responses with checkpoint inhibitors. The planned addition of other treatment modalities converted another 4 patients (40%) to a durable 2nd remission. This sequential approach merits further exploration in prospective clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Kirk Kerkorian School of Medicine at UNLV, Las Vegas, NV, USA.
- Comprehensive Cancer Centers of Nevada, Las Vegas, NV, USA.
- University of Nevada School of Medicine, Reno, NV, USA.
ORCID-Profile: Wolfram Samlowski
Zitieren
APA
Sadrolashrafi, K., & Samlowski, W. (2023). Retreatment of Patients With Metastatic Cutaneous Melanoma Who Relapse After Elective Checkpoint Inhibitor Discontinuation After a Complete Remission. The Oncologist. https://doi.org/10.1093/oncolo/oyad016
Vancouver
Sadrolashrafi K, Samlowski W. Retreatment of Patients With Metastatic Cutaneous Melanoma Who Relapse After Elective Checkpoint Inhibitor Discontinuation After a Complete Remission. The Oncologist. 2023. doi:10.1093/oncolo/oyad016
BibTeX
@article{Sadrolashrafi2023,
author = {Sadrolashrafi, Kaviyon and Samlowski, Wolfram},
title = {Retreatment of Patients With Metastatic Cutaneous Melanoma Who Relapse After Elective Checkpoint Inhibitor Discontinuation After a Complete Remission},
journal = {The Oncologist},
year = {2023},
doi = {10.1093/oncolo/oyad016}
}
EUVIMED